Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism

Cancer Immunology, Immunotherapy

Volumn 60, Issue 4, 2011, Pages 559-573

  Zhang, Jianbin ^a   Zhou, Zhidong ^a,b   Wang, Cheng ^a   Shen, Jiangen ^a   Zheng, Yun ^a   Zhang, Lihuang ^a   Wang, Jianli ^a   Xia, Dajing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b TAIZHOU UNIVERSITY   (China)

Author keywords

Antitumor immunity; Cytokine gene therapy; Cytotoxic T lymphocytes; Interleukin 10; Lymphotactin; Myeloid derived suppressor cells; Natural killer cells; Regulatory T cells

Indexed keywords

ADENOVIRUS VECTOR; CD11B ANTIGEN; CD4 ANTIGEN; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOTACTIN; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; EMBRYO; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL LYMPHOMA; TH2 CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL SEPARATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPHOKINES; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953792293     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0955-5     Document Type: Article

References (44)

1. Jovasevic VM, Gorelik L, Bluestone JA, Mokyr MB (2004) Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity. J Immunol 172:1449-1454 (Pubitemid 38116787)
2. Richter G, Krüger-Krasagakes S, Hein G, Hüls C, Schmitt E, Diamantstein T, Blankenstein T (1993) Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 53(18):4134-4137 (Pubitemid 24146753)
3. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C et al (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112-3123
4. Kundu N, Beaty TL, Jackson MJ, Fulton AM (1996) Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88:536-541 (Pubitemid 26118724)
5. Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697-703 (Pubitemid 29379811)
6. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I (1996) Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184(2):579-584 (Pubitemid 26324111)
7. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O (1999) IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther 6:1705-1712 (Pubitemid 29485945)
8. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson JL, Axelson H, Castaños-Velez E, Ljunggren HG, Malefyt RD, Granger HJ, Ziche M, Bejarano MT (2000) Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 96(7):2568-2573
9. Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177(2):896-904 (Pubitemid 44036590)
10. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT (1996) Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157:231-238 (Pubitemid 26190552)
11. Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M, Velu T (1996) Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7:23-31 (Pubitemid 26119480)
12. Barth RJ Jr, Coppola MA, Green WR (1996) In vivo effects of locally secreted IL-10 on the murine antitumor immune response. Ann Surg Oncol 3:381-386
13. Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP (1999) Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother 22:489-496 (Pubitemid 29526344)
14. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT (1995) Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 182:477-486
15. Ding Y, Qin L, Kotenko SV, Pestka S, Bromberg JS (2000) A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 191:213-224
16. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ et al (1994) Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395-1399
17. Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S, Abrams J, Handel T, Zlotnik A (1997) Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158:1533-1540
18. Hedrick JA, Zlotnik A (1998) Lymphotactin. Clin Immunol Immunopathol 87:218-222 (Pubitemid 28285436)
19. Giancarlo B, Silvano S, Albert Z, Mantovani A, Allavena P (1996) Migratory response of human natural killer cells to lymphotactin. Eur J Immunol 26:3238-3241 (Pubitemid 26411538)
20. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J (1999) Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697-709 (Pubitemid 29168155)
21. Xia DJ, Zhang WP, Zheng S, Wang J, Pan JP, Wang Q, Zhang LH, Hamada H, Cao X (2002) Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther 9:592-601 (Pubitemid 34567776)
22. Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X (2002) Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. J Mol Med 80:585-594
23. Ju DW, Tao Q, Cheng DS, Zhang W, Zhang M, Hamada H, Cao X (2000) Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 7:329-338 (Pubitemid 30119737)
24. Fujii S, Shimizu K, Shimizu T, Lotze MT (2001) Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98:2143-2151
25. Kundu N, Fulton AM (1997) Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 180:55-61 (Pubitemid 27433618)
26. Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, Blankenstein T, Ljunggren HG, Kiessling R (1997) Downregulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159(7):3195-3202 (Pubitemid 127482077)
27. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM (2003) The dual role of IL-10. Trends Immunol 24(1):36-43 (Pubitemid 35462111)
28. Salazar-Onfray F, Petersson M, Franksson L, Matsuda M, Blankenstein T, Kärre K, Kiessling R (1995) IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol 154(12):6291-6298
29. Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161:2099-2105 (Pubitemid 28397018)
30. Cai G, Kastelein RA, Hunter CA (1999) IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol 29:2658-2665 (Pubitemid 30098990)
31. Parato KG, Kumar A, Badley AD, Sanchez-Dardon JL, Chambers KA, Young CD, Lim WT, Kravcik S, Cameron DW, Angel JB (2002) Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. Aids 16:1251-1256 (Pubitemid 34666659)
32. Mocellin S, Panelli M, Wang E, Rossi CR, Pilati P, Nitti D, Lise M, Marincola FM (2004) IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 5:621-630 (Pubitemid 40045300)
33. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442-447 (Pubitemid 17009577)
34. Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy - review of a new approach. Pharmacol Rev 55(2):241-269 (Pubitemid 36666048)
35. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C (1994) Macrophages and angiogenesis. J Leukoc Biol 55:410-422 (Pubitemid 24097250)
36. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927-932 (Pubitemid 28323558)
37. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138-146 (Pubitemid 26074503)
38. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617-627 (Pubitemid 29428646)
39. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32 (Pubitemid 33070205)
40. Hussain SF, Paterson Y (2004) CD4+ CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector. J Immunother 27:339-346 (Pubitemid 39121922)
41. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499-4506
42. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13:828-835 (Pubitemid 47038194)
43. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70(1):68-77
44. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202:931-939 (Pubitemid 41396893)